

Stereoselective synthesis of (2*R*,3*R*) and (2*R*,3*S*)-3-hydroxyleucines[☆]

Sadagopan Raghavan* and K. A. Tony

Organic Division I, Indian Institute of Chemical Technology, Hyderabad 500 007, India

Received 22 November 2003; revised 19 January 2004; accepted 26 January 2004

Abstract—A stereoselective synthesis of (2*R*,3*R*) and (2*R*,3*S*)-3-hydroxyleucine is disclosed. The key step of the reaction sequence involves, stereo- and regioselective bromohydration of **7**, using a brominating agent derived in situ from *N*-bromosuccinimide and 2,6-lutidine, via intramolecular sulfinyl group participation.

© 2004 Elsevier Ltd. All rights reserved.

β -Hydroxy α -amino acids are constituents of many bioactive natural products. (2*S*,3*S*)-3-Hydroxyleucine is a key constituent of a range of naturally occurring cyclic depsipeptides that include telomycin,¹ A-83586C,² azinotricin,³ citropeptin,⁴ varicapeptin,⁴ L-156602,⁵ verucopeptin,⁶ and sanjoinine.⁷ Lysobactin⁸ contains the (2*S*,3*R*) diastereoisomer while lactacystin⁹ incorporates the (2*R*,3*S*) isomer. As a consequence of the essential role played by this amino acid in biological systems and its utility as a synthon, a number of useful strategies have been disclosed for its preparation.¹⁰ The majority of the reported methods utilize, Sharpless asymmetric epoxidation/dihydroxylation reaction or chiral pool starting materials for the introduction of the desired stereocenters. In continuation of our interest in utilizing the sulfinyl group as an intramolecular nucleophile to heterofunctionalize olefins,¹¹ we disclose herein a stereoselective approach to (2*R*,3*R*) and (2*R*,3*S*)-3-hydroxyleucine (Fig. 1).

The bromohydrin **2**, elaborated stereoselectively from the unsaturated ester **1**,^{11c} was subjected to treatment with tetramethylguanidinium azide (TMGA)¹² in dichloromethane to yield stereoselectively the azidoester **3**.^{10k} Treatment of **3** with di-*tert*-butyldicarbonate and Raney-Nickel under an atmosphere of hydrogen in




Figure 1.


ethanol as the solvent yielded cleanly the urethane **4** (Scheme 1), whose physical characteristics¹³ were in good agreement with the data reported in the literature.¹⁴

Aldehyde **5**^{11c} on treatment with methyl(triphenylphosphoranylidene)acetate in benzene as the solvent afforded the *trans* α,β -unsaturated ester **6** exclusively.¹⁵ Oxidation of the sulfide with NaIO₄¹⁶ yielded an epimeric mixture of sulfoxides **7** in equimolar proportions as an inseparable mixture. Bromohydration of **7** with NBS yielded a product mixture of **8** and **9**, stereoisomeric at C3 and C4 in a 3:1 ratio, respectively.¹⁷ After much experimentation varying the solvents, temperature, and the halogenating agent bromohydration, when carried out with NBS in the presence of an equivalent of 2,6-lutidine (relative to NBS), yielded cleanly the bromohydrin **8** (Scheme 2). Probably a new sterically bulkier brominating agent is formed (as an indication of which the reaction proceeds slower) in situ by the reaction of NBS with 2,6-lutidine, which reacts with **7** in a stereoselective fashion.


Keywords: 3-Hydroxyleucine; Intramolecular participation; Bromohydration.

[☆] ICT Communication No. 040110.

* Corresponding author. Tel.: +91-40-2716-0123; e-mail: sraghavan@iict.ap.nic.in



Scheme 1. Reagents and conditions: (a) NBS, H₂O, toluene, rt, 3 h, 80%; (b) TMGA, CH₂Cl₂, 0 °C to rt, 1 h, 80%; (c) H₂, (Boc)₂O, Raney-Ni, EtOH, 60 °C, 2 h, 70%.



Scheme 2. Reagents and conditions: (a) Ph₃PCHCO₂Me, PhH, rt, 3 h, 85%; (b) NaIO₄, MeOH/H₂O (2:1), 0 °C to rt, 5 h, 85%; (c) NBS, H₂O, toluene, rt, 3 h, 75% 3:1 of **8:9**; (d) NBS, H₂O, 2,6-lutidine, toluene, rt, 6 h, 65% of **8** only.


The bromohydrin **8** on treatment with NaN₃ in DMF at rt afforded a mixture of products¹⁸ epimeric at C4. Corey et al.^{10h} in their study aimed at the preparation of (2*S*,3*S*)-3-hydroxyisoleucine made a similar observation, when attempted displacement of the bromide α to the ester by the azido group, yielded the epimeric azides and the epoxide. The side reaction could be averted by silyl protection. Attempted protection of the hydroxy group in **8** as its silyl ether by treatment with *tert*-butyldimethylsilyl triflate and 2,6-lutidine yielded a mixture of products resulting from the activation of the sulfinyl group by the reagent. Therefore the sulfinyl group was reduced¹⁹ to yield the sulfide **10**, which on treatment with *tert*-butyldimethylsilyl triflate cleanly afforded the silyl ether **11**. Displacement of the bromide in **11** proceeded without incident to yield the azide **12** on warming the DMF solution with excess of sodium azide. Treatment of **12** with excess of Raney-Nickel in the presence of (Boc)₂O under an atmosphere of hydrogen

in ethanol as the solvent yielded the silyl ether **13**. Deprotection of the silyl group with TBAF afforded urethane **14**²⁰ (Scheme 3).

In conclusion we have devised a very stereoselective route to (2*R*,3*R*) and (2*R*,3*S*)-3-hydroxyisoleucine diastereomers from the *cis* and *trans* α,β -unsaturated esters **1** and **7**, respectively. The brominating agent generated in situ from NBS and 2,6-lutidine proved to be more stereoselective in the reaction with ester **7**.

Acknowledgements

S.R. is thankful to Dr. J. S. Yadav, Director, I.I.C.T, for constant support and encouragement. K.A.T is thankful to CSIR, New Delhi for a fellowship. Financial assis-



Scheme 3. Reagents and conditions: (a) TiCl₃, EtOH, rt, 30 min 65%; (b) TBS-OTf, 2,6-lutidine, CH₂Cl₂, 0 °C to rt, 1 h, 70%; (c) NaN₃, DMF, 50 °C, 3 h, 65%; (d) H₂, (Boc)₂O, Raney-Ni, EtOH, 60 °C, 2 h, 70%; (e) *n*-Bu₄NF, THF, rt, 2 h, 85%.

tance from DST (New Delhi) is gratefully acknowledged. We thank Dr. A. C. Kunwar for the NMR spectra and Dr. M. Vairamani for the mass spectra.

References and notes

1. Sheehan, J. C.; Maeda, K.; Sen, A. K.; Stock, A. K. *J. Am. Chem. Soc.* **1962**, *84*, 1303.
2. Smita, T. A.; Deeter, J. B.; Hunt, A. H.; Mertz, F. P.; Ellis, R. M.; Boeck, L. D.; Yao, R. C. *J. Antibiot.* **1988**, *41*, 726.
3. Maehr, H.; Liu, C.-M.; Pallerow, N. J.; Smallheer, J.; Todaro, L.; Williams, T. H.; Blout, J. F. *J. Antibiot.* **1986**, *39*, 17.
4. (a) Nakagawa, M.; Hayakawa, Y.; Furihita, K.; Seto, H. *J. Antibiot.* **1990**, *43*, 477; (b) Hayakawa, Y.; Nakagawa, M.; Toda, Y.; Seto, H. *Agric. Biol. Chem.* **1990**, *54*, 1007.
5. Heusens, O. D.; Borris, R. P.; Koupal, L. R.; Caldwell, L. G.; Currie, S. A.; Haidri, A. A.; Honnick, C. F.; Honeysutt, S. S.; Lindenmayer, H. B.; Zink, O. L.; Zitano, L.; Fieldhouse, J. M.; Rollins, T.; Springer, M. S.; Springer, J. P. *J. Antibiot.* **1991**, *44*, 249.
6. Nishiyama, Y.; Sugawara, K.; Tomita, K.; Yamamoto, H.; Kamei, H.; Oki, T. *J. Antibiot.* **1993**, *46*, 921.
7. Han, B. H.; Park, M. H.; Park, J. H. *Pure Appl. Chem.* **1989**, *61*, 443.
8. Tywiak, A. A.; McCormick, T. T.; Unger, S. E. *J. Org. Chem.* **1989**, *54*, 1149.
9. Omura, S.; Fujimoto, T.; Otoguro, K.; Moriguchi, R.; Tanaka, H.; Sasaki, Y. *J. Antibiot.* **1991**, *44*, 113.
10. (a) Xiong, C.; Wang, W.; Hruby, V. J. *J. Org. Chem.* **2002**, *67*, 3514; (b) Davis, F. A.; Srirajan, V.; Fanelli, D. L.; Portonovo, P. *J. Org. Chem.* **2000**, *65*, 7663; (c) Williams, L.; Zhang, Z.; Shao, F.; Carroll, P. J.; Joullie, M. M. *Tetrahedron* **1996**, *52*, 11673; (d) Nagamitsu, T.; Sunazuka, T.; Tanaka, H.; Omura, S.; Sprengeler, P. A.; Smith, A. B., III. *J. Am. Chem. Soc.* **1996**, *118*, 3584; (e) Yadav, J. S.; Chandrasekhar, S.; Ravindra Reddy, Y.; Rama Rao, A. V. *Tetrahedron* **1995**, *51*, 2749; (f) Hale, K. J.; Manaviazar, S.; Delisser, V. M. *Tetrahedron* **1994**, *50*, 9181; (g) Kanemasa, S.; Mori, T.; Tatsukawa, A. *Tetrahedron Lett.* **1993**, *34*, 8292; (h) Corey, E. J.; Lee, D.-H.; Choi, S. *Tetrahedron Lett.* **1992**, *33*, 6735; (i) Caldwell, C. G.; Bondy, S. S. *Synthesis* **1990**, 34; (j) Jung, M. E.; Jung, Y. H. *Tetrahedron Lett.* **1989**, *30*, 6637; (k) Evans, D. A.; Sjogren, E. B.; Weber, A. E.; Conn, R. E. *Tetrahedron Lett.* **1987**, *28*, 39; (l) Seebach, D.; Juaristi, E.; Miller, D. D.; Schickli, C.; Weber, T. *Helv. Chim. Acta* **1987**, *70*, 237.
11. (a) Raghavan, S.; Rasheed, M. A. *Tetrahedron* **2003**, *59*, 10307; (b) Raghavan, S.; Joseph, S. C. *Tetrahedron Lett.* **2003**, *44*, 8237; (c) Raghavan, S.; Rajender, A. *J. Org. Chem.* **2003**, *68*, 7094; (d) Raghavan, S.; Ramakrishna Reddy, S.; Tony, K. A.; Naveen Kumar, Ch.; Varma, A. K.; Nangia, A. *J. Org. Chem.* **2002**, *67*, 5838; (e) Raghavan, S.; Tony, K. A. *J. Org. Chem.* **2003**, *68*, 5002; (f) Raghavan, S.; Rasheed, M. A.; Joseph, S. C.; Rajender, A. *J. Chem. Soc., Chem. Commun.* **1999**, 1845.
12. Evans, D. A.; Britton, T. C.; Ellmann, J. A.; Dorow, R. L. *J. Am. Chem. Soc.* **1990**, *112*, 4011.
13. ¹H NMR (200 MHz, CDCl₃) δ 5.4 (d, *J* = 6.8 Hz, 1H), 4.40 (dd, *J* = 7.9, 3.4 Hz, 1H), 3.75 (s, 3H), 3.42 (br s, 1H), 1.7 (m, 1H), 1.45 (s, 9H), 1.02 (d, *J* = 6.4 Hz, 3H), 0.96 (d, *J* = 6.8 Hz, 3H). ¹³C NMR (75 MHz, CDCl₃) 19.0, 19.2, 28.1, 30.6, 52.2, 78.6, 80.1, 153.4, 171.7.
14. Schmidt, U.; Respondek, M.; Lieberknecht, A.; Werener, J.; Fischer, P. *Synthesis* **1989**, 256.
15. The stereochemical integrity of the chiral center during the transformation of the aldehyde **5** to the unsaturated ester **6** was proven by a two step transformation of the latter including (i) reduction to the allyl alcohol using DIBAL-H and (ii) reaction of the allyl alcohol with (*S*)-*O*-methyl mandelic acid using DCC, to yield diastereomerically pure mandelate ester.
16. Leonard, N. J.; Johnson, C. R. *J. Org. Chem.* **1962**, *27*, 282.
17. Oxidation of the mixture of sulfoxides **8** and **9** with *m*-CPBA afforded the corresponding sulfones. Integration of the C3 methine proton signal of the sulfone mixture revealed the presence of the stereoisomers in a 3:1 ratio.
18. The product distribution was not any different using TMGA in dichloromethane.
19. Takahashi, T.; Iyobe, A.; Arai, Y.; Koizumi, T. *Synthesis* **1989**, 189.
20. ¹H NMR (200 MHz, CDCl₃) δ 5.20 (d, *J* = 9.5 Hz, 1H), 4.40 (d, *J* = 8.8 Hz, 1H), 3.75 (s, 3H), 3.65 (d, *J* = 9.5 Hz, 1H), 1.70 (m, 1H), 1.45 (s, 9H), 1.0 (d, *J* = 6.6 Hz, 3H), 0.90 (d, *J* = 6.6 Hz, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 18.9, 28.3, 30.8, 52.4, 55.6, 80.0, 156.0, 172.7.